Duzallo

Hyperuricemia, Lesch-Nyhan Syndrome, Chemotherapy + 15 more
Treatment
16 FDA approvals
20 Active Studies for Duzallo

What is Duzallo

AllopurinolThe Generic name of this drug
Treatment SummaryGout is an inflammatory condition caused by the accumulation of monosodium urate crystals in the body, especially around joints. It has been known since ancient times and has been documented in medical records and biographies. Allopurinol is a common medication used to reduce urate levels and treat chronic gout. It was approved by the FDA in 1966 and is now made by several different companies.
Zyloprimis the brand name
image of different drug pills on a surface
Duzallo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zyloprim
Allopurinol
1966
270

Approved as Treatment by the FDA

Allopurinol, also called Zyloprim, is approved by the FDA for 16 uses such as Kidney Calculi and female patients with daily uric acid excretion that exceeds 750 mg/day .
Kidney Calculi
female patients with daily uric acid excretion that exceeds 750 mg/day
Cancer
Hyperuricemia
Leukemias
Malignant Lymphomas
Arthritis, Gouty
Used to treat Gouty Arthritis in combination with Lesinurad
failed previous allopurinol monotherapy
Used to treat failed previous allopurinol monotherapy in combination with Lesinurad
Hyperuricemia
Hyperuricemia
Chemotherapy
Lymphoma, Non-Hodgkin
Leukemia
Symptomatic
Secondary gout
Primary Gout

Effectiveness

How Duzallo Affects PatientsAllopurinol works by reducing the amount of uric acid the body makes. This helps to relieve the symptoms of gout such as painful swelling, joint pain, redness, and difficulty moving.
How Duzallo works in the bodyAllopurinol helps reduce gout symptoms by blocking an enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. This drug also increases the amount of hypoxanthine and xanthine for nucleotide and nucleic acid synthesis. As a result, uric acid levels in the urine and blood drop, which reduces the risk of gout symptoms. Allopurinol also encourages the dissolution of existing gout tophi by lowering the amount of uric acid in the blood below its solubility limit. Although hypoxanthine and xanthine levels increase after allop

When to interrupt dosage

The recommended dosage of Duzallo is contingent upon the diagnosed condition, including Gout Flares, Leukemias and Cancer. The amount of dosage is contingent on the method of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Tablet, film coated - Oral) provided in the following table.
Condition
Dosage
Administration
Symptomatic
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Chemotherapy
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Chronic Kidney Disease (CKD)
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Metabolic Diseases
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Gout Flares
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Eczema
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Leukemia
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Primary Gout
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Hyperuricemia
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Lesch-Nyhan Syndrome
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Arthritis, Gouty
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Kidney Calculi
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
female patients with daily uric acid excretion that exceeds 750 mg/day
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
failed previous allopurinol monotherapy
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Hyperuricemia
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Urinary Bladder Calculi (disorder)
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Lymphoma, Non-Hodgkin
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Secondary gout
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Duzallo.
Common Duzallo Drug Interactions
Drug Name
Risk Level
Description
Didanosine
Major
The serum concentration of Didanosine can be increased when it is combined with Allopurinol.
Oteracil
Major
The therapeutic efficacy of Oteracil can be decreased when used in combination with Allopurinol.
Pegloticase
Major
The risk or severity of adverse effects can be increased when Allopurinol is combined with Pegloticase.
Abacavir
Minor
Allopurinol may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Allopurinol may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Duzallo Toxicity & Overdose RiskThe lowest toxic dose for rats is 10 mg/kg, while the lowest toxic dose for mice is 78 mg/kg. Reproductive studies on rats and rabbits have not shown any adverse effects, but there have been reports of increased numbers of dead fetuses and malformations in pregnant mice given 50 or 100 mg/kg allopurinol. Nursing women should be cautious while taking allopurinol as it has been found in the milk of a nursing mother. Studies have not found allopurinol to be mutagenic or carcinogenic.
image of a doctor in a lab doing drug, clinical research

Duzallo Novel Uses: Which Conditions Have a Clinical Trial Featuring Duzallo?

560 active clinical trials are investigating the potential of Duzallo to mitigate Kidney Disease, Chemotherapy-related complications and Metabolic Diseases.
Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease (CKD)
31 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1
failed previous allopurinol monotherapy
0 Actively Recruiting
Secondary gout
0 Actively Recruiting
Lymphoma, Non-Hodgkin
1 Actively Recruiting
Phase 1
Leukemia
1 Actively Recruiting
Not Applicable
Eczema
9 Actively Recruiting
Phase 2, Early Phase 1, Not Applicable, Phase 3
Lesch-Nyhan Syndrome
0 Actively Recruiting
Arthritis, Gouty
0 Actively Recruiting
Hyperuricemia
0 Actively Recruiting
Chemotherapy
4 Actively Recruiting
Phase 1, Phase 3, Not Applicable
female patients with daily uric acid excretion that exceeds 750 mg/day
0 Actively Recruiting
Kidney Calculi
0 Actively Recruiting
Metabolic Diseases
2 Actively Recruiting
Not Applicable
Hyperuricemia
3 Actively Recruiting
Phase 3, Phase 1
Urinary Bladder Calculi (disorder)
0 Actively Recruiting
Primary Gout
0 Actively Recruiting
Gout Flares
1 Actively Recruiting
Phase 2
Symptomatic
0 Actively Recruiting

Duzallo Reviews: What are patients saying about Duzallo?

3.7Patient Review
10/21/2018
Duzallo for Treatment to Prevent Gout
I experienced a lot of side effects with this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about duzallo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does allopurinol do?

"This medication is used to lower the level of uric acid in your blood. Uric acid build-up can cause tiny, sharp crystals to form in and around your joints, which is a condition known as gout. Kidney stones can also be caused by too much uric acid. Allopurinol is used to prevent these conditions from occurring or to lessen their symptoms."

Answered by AI

Why was lesinurad discontinued?

"- The FDA has announced the discontinuation of Ironwood Pharmaceuticals' Duzallo (lesinurad/allopurinol) and Zurampic (lesinurad). This is due to business reasons and not because of any safety, efficacy or quality issues."

Answered by AI

What is Duzallo used for?

"Duzallo is a medication used to lower uric acid levels in adults with gout. It is typically given when allopurinol alone has not been effective."

Answered by AI

Clinical Trials for Duzallo

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA
The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
Waitlist Available
Has No Placebo
UPMC Hillman Cancer CenterCarissa A Low
Have you considered Duzallo clinical trials? We made a collection of clinical trials featuring Duzallo, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Inspire HER for Cardiovascular Disease

30 - 79
Female
Birmingham, AL
Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamTimiya S Nolan, PhD
Have you considered Duzallo clinical trials? We made a collection of clinical trials featuring Duzallo, we think they might fit your search criteria.Go to Trials
Image of South Florida Research Institute in Lauderdale Lakes, United States.

Mezagitamab for Berger's Disease

18+
All Sexes
Lauderdale Lakes, FL
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time. In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.
Phase 3
Recruiting
South Florida Research Institute (+15 Sites)Study DirectorTakeda
Image of PAREXEL International - Early Phase Clinical Unit Baltimore in Baltimore, United States.

NNC4004-0002 for High Uric Acid

35 - 75
All Sexes
Baltimore, MD
This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.
Phase 1
Recruiting
PAREXEL International - Early Phase Clinical Unit Baltimore (+2 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S
Have you considered Duzallo clinical trials? We made a collection of clinical trials featuring Duzallo, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security